Provided by Tiger Trade Technology Pte. Ltd.

Moleculin Biotech

0.6537
+0.00901.40%
Volume:242.77K
Turnover:155.03K
Market Cap:12.73M
PE:-0.07
High:0.6548
Open:0.6400
Low:0.6200
Close:0.6447
52wk High:15.75
52wk Low:0.1614
Shares:19.48M
Float Shares:17.03M
Volume Ratio:0.34
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.5973
EPS(LYR):-28.4188
ROE:-1371.64%
ROA:-84.57%
PB:1.10
PE(LYR):-0.02

Loading ...

Moleculin Biotech Stockholders Approve Warrant Share Issuance

TIPRANKS
·
Apr 15

Moleculin CEO highlights Annamycin’s non-cardiotoxic profile in CEO Corner interview

Reuters
·
Apr 08

Moleculin Biotech management to meet with Maxim

TIPRANKS
·
Apr 02

Moleculin Biotech files to sell 6.37M shares of common stock for holders

TIPRANKS
·
Mar 28

Moleculin Biotech Price Target Maintained With a $22.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 24

Moleculin enrolls 45th patient in MIRACLE AnnAraC trial for relapsed or refractory AML

Reuters
·
Mar 23

Moleculin Biotech: Attractive Risk/Reward Ahead of Pivotal Annamycin Phase 3 Readout Supports Buy Rating and $10 Target

TIPRANKS
·
Mar 21

Moleculin Biotech Q4 EPS $(26.06) Misses $(11.60) Estimate

Benzinga Earnings
·
Mar 19

Moleculin Biotech Updates Investors with New Corporate Presentation

TIPRANKS
·
Mar 19

Moleculin Biotech targets mid-2026 unblinding of 45-patient interim data in Phase 2B/3 MIRACLE Annamycin AML trial

Reuters
·
Mar 19

Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal Miracle Trial on Track for Mid-2026

THOMSON REUTERS
·
Mar 19

Moleculin Biotech Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 19

Moleculin Biotech FY 2025 net loss widens 28.9% to USD 33.56 million

Reuters
·
Mar 19

Moleculin Biotech to present at ROTH Conference fireside chat

Reuters
·
Mar 17

Moleculin Biotech Inc expected to post a loss of $6.11 a share - Earnings Preview

Reuters
·
Mar 17

Moleculin Biotech says MIRACLE Phase 3 AML trial enrollment and dosing progress as planned

Reuters
·
Mar 11